New MyoStrain® Webinar
Find out how MyoStrain® can help cancer patients in our latest cardio-oncology webinar by the European Society of Cardiology.
Learn MoreFind out how MyoStrain® can help cancer patients in our latest cardio-oncology webinar by the European Society of Cardiology.
Learn More
MyoStrain is transforming the way physicians manage and monitor patient heart health, providing a proactive, patient-centric solution to help physicians improve outcomes and prevent heart failure.
Watch Video >Today's diagnostics often cannot detect heart dysfunction until symptoms occur. MyoStrain utilizes segmental strain to measure 48 segments of the heart and provides physicians with a unique diagnostic tool to help identify regional dysfunction before the heart as a whole is effected.
.svg)
MyoStrain uses segmental strain to help physicians detect regional heart dysfunction early and before global heart function is impacted.¹ Measured across 48 segments of the heart, MyoStrain helps physicians determine weaker areas of the heart where abnormal contraction is occurring.
As shown below, using segmental strain allows physicians to differentiate and measure weak, or abnormal, heart segments. Conversely, because global strain measures the heart as a whole, healthy segments often overcompensate for abnormal segments, making the heart appear healthy.
MyoStrain is a rapid MRI-based heart function test that quantifies the effects of disease, drugs, and ischemia across 48 heart segments in under 10 minutes.
Patients undergo a six-heartbeat MRI scan without the need for radiation, contrast, or breath-hold
Directly measures the percentage of normally contracting myocardium across 48 segments
Provides high reproducibility across sites, operators and MR vendors
Creates a personalized patient report, helping physicians make individualized treatment decisions
From the MyoStrain report, physicians are given a MyoHealth Score, a single, standardized metric indicating the percentage of normal heart segments.
Example of monitoring cardio-protective therapy during chemotherapy
For cancer patients who may be at a higher risk of developing heart failure, the MyoHealth score provides solutions to help cardio-oncologists manage cardio-protection over time without interfering with cancer treatment.
Over 10 million Americans visit the ER with unexplained chest pain symptoms every year.¹ In 10-15 minutes, the MyoHealth score may help physicians to quickly risk stratify patients and refer patients towards optimal treatment pathways.
Nearly half of Americans will have some form of cardiovascular disease by 2035.² MyoStrain helps physicians to quantify the effects of heart diseases on patient heart function, enabling preventative care pathways for patients at risk of heart failure.
Over half of acute heart failure patients are re-hospitalized within six months.³ MyoHealth scores help physicians monitor and manage the effects of treatment to reduce hospitalizations and improve quality of life.
Myocardial Solutions is pursuing the next standard of care in cardiology. Through MyoStrain, our focus is to transform cardiac care to heart failure prevention and standardized patient management.
We're here to answer your questions. Learn how MyoStrain can help transform your cardiac practice.
REFERENCES
1. Hsia R. et al. A National Study of the Prevalence of Life-Threatening Diagnoses in Patients With Chest Pain. JAMA Intern Med. 2016;176(7):1029-1032. doi:10.1001/jamainternmed.2016.2498
2. American Heart Association. CVD Burden Report 2017.
3. Lesyuk W, et al. BMC Cardio D 2018.
4. Savarese G, et al. Card Fail Rev 2017. doi:10.15420/cfr.2016:25:2
